[18F] APN-1607 for Supranuclear Palsy, Progressive
This study is evaluating whether a PET radiotracer can measure tau pathology in people with progressive supranuclear palsy.
See full descriptionAbout the trial for Supranuclear Palsy, Progressive
Treatment Groups
This trial involves 2 different treatments. [18F] APN-1607 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether [18F] APN-1607 will improve 1 primary outcome in patients with Supranuclear Palsy, Progressive. Measurement will happen over the course of 72 weeks.
Patient Q & A Section
Has [18f] apn-1607 proven to be more effective than a placebo?
[18F]APN reflects dopaminergic activity in the presynaptic striatum of the [18F] DOPA-PET. A study of 15 untreated patients with progressive supranuclear palsy showed that a single injection of [18F]APN had significantly better effects than a placebo scan.
Does supranuclear palsy, progressive run in families?
Genetic susceptibility to PD, but not SP, was identified. Despite the rarity of PD and SP, it was found to run in parallel families. The finding of an association between PD and SP should cause caution.
What are common treatments for supranuclear palsy, progressive?
Treatment in progressive supranuclear palsy is tailored to the needs of each patient. It is common for patients to experience a dramatic effect on their symptoms with several different medical therapies, often from different professional providers. One type of medical therapy that is often recommended is anti-Parkinsonism drugs.
Can supranuclear palsy, progressive be cured?
The authors propose that while some measures of movement control can be improved, overall the progression of choreic symptoms is intractable, and therefore progressive supranuclear palsy (PSP) is intrinsically unfixable with current treatments.
What is supranuclear palsy, progressive?
Palsy of the abducens nerve most commonly affects people between the ages of 50 and 60. The diagnosis can be made by visual examination and by the gradual, gradual onset of progressive, upper motor neuron, unilateral, descending, sensory loss on the affected half of the face, and loss of abduction (turning back the eyeball) when the affected eye is asked to gaze at a near target from the side. The diagnosis may be confirmed through further nerve conduction studies, nerve imaging, and electrophysiologic recordings from the affected eye. There is no definite treatment. There have been few well-designed, randomized controlled trials of medications to treat PALS.
What are the signs of supranuclear palsy, progressive?
The key sign is a brisk startle response by asking an obvious question about the patient. The diagnosis of SPP should be strengthened by an MRI. This technique helps to show the anatomical location and pattern of the disease, as well as its progression.
How many people get supranuclear palsy, progressive a year in the United States?
Around 35,000 people in the United States get PSP, with about a tenth of these having it bilaterally. Rates of PSP in the United States are higher than rates in the rest of the world. PSP is the most common cause of progressive extrapyramidal symptoms in the elderly and has a relatively high prevalence in the USA.
What causes supranuclear palsy, progressive?
It is not possible to determine a specific cause of PSP. However, the study found that a strong genetic component was associated with PSP and that there are multiple, additive environmental risk factors that may produce an exacerbation of already increased risk of PSP; these variables can include environmental factors that are stressful and stressful life events.
Is [18f] apn-1607 safe for people?
[18F] apn-1607 is a good radiotracer for PET imaging in people with progressive supranuclear palsy or atypical Parkinson disease due to its low liver and kidney metabolism and low [18F]-fluoride content.
What are the latest developments in [18f] apn-1607 for therapeutic use?
APN-1607 was found to be effective in pre-clinical models of PD. Recent findings led to a clinical trial (ADAGEN-001), which began on 23 December 2012.
What is the primary cause of supranuclear palsy, progressive?
There is strong evidence indicating that the [cranial nerves do. not. stretch in space] that are the principal sites of primary neuromuscular junction dysfunction among patients with progressive supranuclear palsy. The mechanisms which cause the cranial neural system to develop in this manner and the mechanisms which generate the specific atrophy-caused symptoms which characterize this condition are both unclear and of continuing investigation. The progressive supranuclear palsy syndrome is probably best viewed as an extreme (toxic) of its own category of diseases that cause changes in cranial nerve structure, and a set of clinical-pathologic considerations which are discussed.
What are the common side effects of [18f] apn-1607?
Patients with mild to moderate [18F] apn-1607 exposure had similar side effect profiles to patients with untreated [18F] apn-1607 binding. The most common side effects in patients treated with apn-1607 were headache and fatigue which occurred in approximately 30% and 20% of patients, respectively. The frequency of these side effects was related to the time spent in the PET scanner. There was no significant difference in the frequency of any side effects when comparing male and female patients. The most common side effects were not related to the frequency of side effects in other [18F] apn-1607-treated studies.